ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,035.69
-1.57%
Dow Jones
37,815.92
0.00%
US Dollar vs MXN
17.09455
-0.34%
Brent Oil
84.99
-1.05%
Bitcoin
57,704.94
-4.78%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) Noticias

RGNX REGENXBIO Inc

15.35
0.00 (0.00%)
Pre Mercado
Última actualización: 06:00:05
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
REGENXBIO Inc RGNX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 15.35 06:00:05
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
15.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202406:05PRNUSREGENXBIO to Host Conference Call on May 8 to Discuss First..
24/4/202406:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28/3/202406:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27/3/202415:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11/3/202407:00EDGAR2Form 8-K - Current report
11/3/202406:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/3/202405:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/3/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202405:03EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/3/202422:20PRNUSREGENXBIO Announces Pricing of Upsized Public Offering of..
06/3/202415:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202415:10PRNUSREGENXBIO Announces Proposed Public Offering of Common Stock
05/3/202415:26EDGAR2Form 144 - Report of proposed sale of securities
05/3/202406:05PRNUSREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM..
29/2/202415:57PRNUSREGENXBIO to Host Webcast Event to Discuss New Interim..
27/2/202415:54EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202415:10EDGAR2Form 8-K - Current report
27/2/202415:05PRNUSREGENXBIO Reports Fourth Quarter and Full Year 2023..
21/2/202406:05PRNUSREGENXBIO to Host Conference Call on February 27 to Discuss..
16/2/202417:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202410:40PRNUSREGENXBIO Announces Pivotal Trial of RGX-121 for the..
07/2/202406:05PRNUSREGENXBIO Announces Completion of Enrollment in Cohort 2 and..
31/1/202406:05PRNUSREGENXBIO Announces Presentations at the 20th Annual..
18/1/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202415:22EDGAR2Form 144 - Report of proposed sale of securities
16/1/202413:47PRNUSREGENXBIO Announces Positive Interim Data from Phase II..
10/1/202406:05PRNUSREGENXBIO Announces Presentation at the Hawaiian Eye and..
08/1/202406:05PRNUSU.S. District Court Issues Decision on REGENXBIO and..
04/1/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:21EDGAR2Form 144 - Report of proposed sale of securities
21/12/202312:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:29EDGAR2Form 144 - Report of proposed sale of securities
29/11/202306:05PRNUSREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE®..
08/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:10EDGAR2Form 8-K - Current report
08/11/202315:05PRNUSREGENXBIO Announces Updated Strategic Plans and Third..
07/11/202306:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
03/11/202317:53PRNUSREGENXBIO Presents Positive One Year Data from Phase II..
01/11/202306:05PRNUSREGENXBIO to Host Conference Call on November 8 to Discuss..
30/10/202306:05PRNUSREGENXBIO Announces Presentations at the American Academy of..
05/10/202306:05PRNUSREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
03/10/202315:05PRNUSREGENXBIO Presents Interim Clinical Data from Phase I/II..
26/9/202306:05PRNUSREGENXBIO Announces Presentations at the 28th Annual..
05/9/202306:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
01/9/202315:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/9/202315:12EDGAR2Form 8-K - Current report
30/8/202306:05PRNUSInitial Clinical Data of First Pediatric CLN2 Patient Dosed..

Su Consulta Reciente

NASDAQ
RGNX
REGENXBIO
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados